FEB 17, 2019 3:17 PM PST

Drug Combination May Become Standard Treatment for Metastatic Kidney Cancer

WRITTEN BY: Nouran Amin

Reporting from results of a phase 3 clinical trial, patients with metastatic kidney cancer may soon receive a new standard treatment involving a combination of two drugs. The drugs, axitinib plus the immunotherapeutic agent avelumab, were seen to significantly decrease tumor size better that the current treatment involving the drug sunitinib (Sutent), used specifically in the treatment of renal cell carcinoma.

Learn more about kidney cancers:

"Patients receiving the drug combination also had a higher response rate -- meaning their tumors shrank -- than the sunitinib-only group," says Toni K. Choueiri, MD, senior and co-corresponding author of the report and The Jerome and Nancy Kohlberg Professor of Medicine at Harvard Medical School. "This is certainly better than sunitinib -- hopefully this will lead to Food and Drug Administration approval soon.”

The drug combination, particularly involving the immunotherapeutic—avelumab, works by not only targeting the vascular endothelial growth factor receptor (VEGFR) to disrupt the blood supply to tumors but by also inhibiting and immune checkpoint called PD-L1 which naturally works to exhausts immune T cells—this will ensure the effective attack of cancer cells.

"Interestingly, the analysis showed that all subgroups -- good, intermediate, and poor-risk patient -- benefited from the combination treatment," said Choueiri. This was the topic of an oral presentation Choueiri has just given at the 2019 Genitourinary Cancers Symposium in San Francisco. The results were simultaneously published in the New England Journal of Medicine.

Almost all patients in the study experienced some form of side effects—with the most frequent being thyroid disorders in the drug combination group. However, Dr. Choueiri states that for patients with advanced stage of cancer, the drug combination will serve as "an important option. What we're doing in advanced kidney cancers is pushing the envelope -- these treatments may not be curative, but patients are living longer, and the disease is becoming more chronic."

Source: Dana-Farber Cancer Institute

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
NOV 12, 2021
Cannabis Sciences
Battle of the Cannabinoids: Which Cannabis Compound Could Most Effectively Treat IBD?
NOV 12, 2021
Battle of the Cannabinoids: Which Cannabis Compound Could Most Effectively Treat IBD?
With 3 million people from the U.S. reporting clinical cases in 2015 – accompanied by an increased projected incid ...
NOV 23, 2021
Infographics
The Health Benefits of Cannabis
NOV 23, 2021
The Health Benefits of Cannabis
Legislation is opening more and more doors for cannabis- causing an explosion in both research and marketing campaigns f ...
NOV 30, 2021
Cannabis Sciences
To Trust or Not to Trust the Process: Bioreactive Chemical Variation in Cannabis Extracts Based on Extraction Method
NOV 30, 2021
To Trust or Not to Trust the Process: Bioreactive Chemical Variation in Cannabis Extracts Based on Extraction Method
With cannabis legislation becoming increasingly less restrictive over the past 20 years, consumers have found themselves ...
DEC 02, 2021
Health & Medicine
Senate Bill 8 Increases Demand for Birth Control
DEC 02, 2021
Senate Bill 8 Increases Demand for Birth Control
Since enforcing Senate Bill 8 for stricter abortion laws, Texas has seen an increased demand for birth control. Also kno ...
DEC 19, 2021
Cancer
An Antibody to Clear the Way for Drug Delivery to Tumors
DEC 19, 2021
An Antibody to Clear the Way for Drug Delivery to Tumors
Tumors require blood vessels to obtain nutrients and growth factors needed for their expansion.  Many tumors effici ...
DEC 29, 2021
Plants & Animals
The Blueprint for a Potential Dog Allergy Vaccine
DEC 29, 2021
The Blueprint for a Potential Dog Allergy Vaccine
Dog allergies are becoming increasingly common; some estimates suggest that 10-20% of the world’s population has s ...
Loading Comments...